Elisabetta Bianchi
119 works · 5,703 citations · h-index 38
Top works
- Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments
- Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein
- Solid Phase Synthesis of Peptide C-Terminal Thioesters by Fmoc/t-Bu Chemistry
- Activity of purified hepatitis C virus protease NS3 on peptide substrates
- A designed metal-binding protein with a novel fold
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- Identification of Amino Acid Residues in CD81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E2
- Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products
- Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus
- Substrate Specificity of the Hepatitis C Virus Serine Protease NS3
- A Continuous Assay of Hepatitis C Virus Protease Based on Resonance Energy Transfer Depsipeptide Substrates
- Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination
- Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody
- Structural Analysis of the Epitope of the Anti-HIV Antibody 2F5 Sheds Light into Its Mechanism of Neutralization and HIV Fusion
- A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease
- A Conformationally Homogeneous Combinatorial Peptide Library
- Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies
- Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
- A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
- A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors